Century Therapeutics, Inc. (IPSC)
NASDAQ: IPSC · Real-Time Price · USD
1.260
0.00 (0.00%)
Nov 4, 2024, 4:00 PM EST - Market closed
Century Therapeutics Employees
As of December 31, 2023, Century Therapeutics had 165 total employees, including 152 full-time and 13 part-time employees. The number of employees decreased by 19 or -10.33% compared to the previous year.
Employees
165
Change (1Y)
-19
Growth (1Y)
-10.33%
Revenue / Employee
$12,370
Profits / Employee
-$796,285
Market Cap
106.74M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 165 | -19 | -10.33% |
Dec 31, 2022 | 184 | -4 | -2.13% |
Dec 31, 2021 | 188 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Harvard Bioscience | 416 |
EDAP TMS | 307 |
Immunic | 77 |
Assembly Biosciences | 65 |
Sensus Healthcare | 35 |
Relmada Therapeutics | 20 |
Regencell Bioscience Holdings | 12 |
Coya Therapeutics | 8 |
IPSC News
- 18 hours ago - Century Therapeutics to Present at Guggenheim's Inaugural Healthcare Innovation Conference - GlobeNewsWire
- 5 weeks ago - Century Therapeutics Strengthens Leadership Team with Appointments of Chief Financial Officer and Chief Scientific Officer - GlobeNewsWire
- 3 months ago - Century Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 4 months ago - Century Therapeutics: Cell Therapy Biotech With Expanded Potential Of CNTY-101 - Seeking Alpha
- 5 months ago - Century Therapeutics Presents Interim Results from Phase 1 ELiPSE-1 Study at ASCO 2024 Annual Meeting - GlobeNewsWire
- 6 months ago - Century Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 6 months ago - Century Therapeutics to Present at Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit - GlobeNewsWire
- 7 months ago - Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics - GlobeNewsWire